ASX:ANR Anatara Lifesciences (ANR) Stock Price, News & Analysis → The ONE AI sSock to own now. (It’s not Nvidia.) (From Weiss Ratings) (Ad) Free ANR Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolume3,950 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Anatara Lifesciences alerts: Email Address Ad Behind the MarketsThe only AI company you should be looking atThis is the ONLY AI company you should be watching right now. No. It's not Nvidia, Intel, or Microsoft... It's a tiny biotech using proprietary AI to assist in new drug discovery at a rate 100,000 times faster than a human. This new drug discovery technique will change the market. And that's why they received a $50 million investment from an AI powerhouse.Get the stock ticker here >>> About Anatara LifesciencesAnatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.Read More Ad InvestorPlaceThey said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.There are five coins you must take a look at right away. ANR Stock News HeadlinesJanuary 23, 2024 | forbes.comEdwards LifesciencesOctober 5, 2023 | wsj.comEris Lifesciences Ltd.March 19, 2024 | Colonial Metals (Ad)Central Bank Gold Heist In ProgressWhen central banks buy gold… The rich buy right along with them. And central banks are buying at breakneck pace. Last year… 1,037 tons. Just 45 tons less than the record set two years ago.August 9, 2023 | finance.yahoo.comEdwards Lifesciences (EW) Q2 Earnings Top Estimates, View UpJune 16, 2023 | wsj.comMega Lifesciences PCLMay 10, 2023 | wsj.comZydus Lifesciences Ltd.April 4, 2023 | proactiveinvestors.com.auInnovation begins with collaboration: Steven LydeamoreMarch 29, 2023 | finance.yahoo.comAnatara Lifesciences Ltd (ANR.AX)March 19, 2024 | Porter & Company (Ad)Urgent new message from Porter StansberryI’ve been in the financial markets for close to three decades… Yet, I’ve never seen an opportunity that’s so urgent, so critical, and yet so overlooked than what is unfolding right now. You see, in one corner of the markets a financial anomaly has emerged that promises to be the single most important story of 2024.March 11, 2023 | benzinga.comEdwards Lifesciences Stock (NYSE:EW), DividendsSeptember 21, 2022 | reuters.comAnatara Lifesciences LtdSeptember 7, 2021 | investing.comAnatara Lifesciences Ltd (ANR)September 6, 2021 | sg.finance.yahoo.comAnatara Lifesciences Limited (ANR.AX) Meet the CEO Investor WebinarSeptember 6, 2021 | uk.finance.yahoo.comAnatara Lifesciences Limited (ANR.AX) Investor PresentationAugust 20, 2021 | au.finance.yahoo.comAnatara Lifesciences Limited (ANR.AX) Launches IBS-D Clinical Trial Recruitment WebsiteAugust 6, 2021 | au.finance.yahoo.comAnatara Lifesciences Limited (ANR.AX) Successful Piglet StudyJuly 28, 2021 | uk.finance.yahoo.comAnatara Lifesciences Limited (ANR.AX) Monthly Activities ReportSee More Headlines Receive ANR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anatara Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolASX:ANR CUSIPN/A CIKN/A Webwww.anataralifesciences.com Phone61 7 3394 8202FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,750,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-117.14% Return on Assets-65.37% Debt Debt-to-Equity Ratio3.24 Current Ratio8.90 Quick Ratio4.69 Sales & Book Value Annual Sales$1.25 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.33 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares167,890,000Free FloatN/AMarket CapN/A OptionableNot Optionable Beta0.65 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. David Lionel Brookes F.A.C.I.D. (Age 64)FACRRM, FAICD, MBBS, Executive Chairman Comp: $168.21kMr. John Michailidis B.Sc.EMBA, M.A.I.C.D., COO & Executive DirectorMr. Simon ErskineChief Development OfficerJane LoweManaging Director of IR DepartmentDr. Stephen Denaro AGIABCom, CA, GradDipApp CG, MAICD, Company SecretaryMs. Hayley van der Meer B Biomed ScGrad Dip Marketing Management, Commercial ManagerMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF45525 (CUR.TO)TSE:CUR60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFView All CompetitorsInsidersJohn MichailidisSold 250,000 sharesTotal: $5,500.00 ($0.02/share)David BrookesSold 725,716 sharesTotal: $15,965.75 ($0.02/share) ANR Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Anatara Lifesciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anatara Lifesciences investors own include Woodside Petroleum (WPL), Temple & Webster Group (TPW), Brompton Oil Split (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP). This page (ASX:ANR) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressLike Tiny Crypto Retirement FundsCrypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceStock-Picking AI Predicts #1 Stock of 2024AltimetrySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyThe world’s greatest investmentPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anatara Lifesciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.